GLEEVEC® is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. GLEEVEC® is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy). GLEEVEC® is also...Read More

Raising Awareness was our Key Motivator! There are about 5,100 Canadians living with CML. Every day someone in Canada is diagnosed with CML Although we have made significant improvements, once a week someone living with CML in Canada will die. No known cause or prevention of CML Some patients in Canada still struggle to access and/or pay...Read More

We are excited to announce that there is another new option that will soon be available for Canadian CML patients in Canada.  Pending Pan Canadian Oncology Drug Review and INESS Approval. ARIAD ANNOUNCES APPROVAL OF ICLUSIG (AS PONATINIB HYDROCHLORIDE) IN CANADA Cambridge, MA, April 6, 2015 –- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that...Read More

ICLUSIG ™ ICLUSIG ™ (Ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ALL that is T315I mutation positive or...Read More

Import Expert Panel advice for CML Patients: Advice for people with chronic myeloid leukemia on COVID-19The iCMLf is sharing an expert statement specifically for chronic phase CML patients on the novel coronavirus and the COVID-19 disease. The novel Coronavirus and the COVID-19 DiseaseInformation for Chronic Phase Chronic Myeloid Leukemia PatientsState of the Art as of...Read More

Notice regarding independent patient activities linked to the generic imatinib mesylate issue:  The CML Society of Canada does not endorse or condone independent patient activity that is aimed at inciting other patients, friends and family members to SPAM government offices with email alleging that generic imatinib mesylate is harmful to patients.  In fact there is...Read More

It is with great sadness that we mark the passing of Dr. Connie Eaves. Dr. Franc Nicolini from the FLMC group wrote a very touching memoriam for Dr. Eaves, click on the link below: C. Eaves pour le site Fi-LMC vdef 10.03.2024Read More

Novartis Pharmaceuticals Canada Inc. (Novartis) has received approval from Health Canada for PrJAKAVI® (ruxolitinib tablets), a drug for the treatment of disease-related splenomegaly (enlarged spleen) and/or its associated symptoms in adult patients with myelofibrosis (MF), a blood cancer.[i] PrJAKAVI® is the first and only JAK 1 and JAK 2 inhibitor approved by Health Canada for...Read More

Self advocating allows the knowledgeable CML patient to become a highly engaged patient.  Studies have shown that engaged patients may have a higher success rate of achieving better results with their overall health care (ref 1.) We have developed some very cool tools to help you get started towards your own journey of empowerment. Click...Read More

Muchas gracias por tomarse el tiempo para completar la encuesta! Importancia de esta investigación Esta investigación es importante porque ayuda a mejorar nuestra comprensión de la experiencia del paciente en términos de calidad de vida mientras que reciben tratamiento para la Leucemia mieloide crónica Beneficios y puede ayudar a crear o perfeccionar programas o planes de tratamiento...Read More